Tāwharau Ora - School of Veterinary Science, Massey University, Palmerston North, New Zealand.
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada.
N Z Vet J. 2024 Sep;72(5):241-255. doi: 10.1080/00480169.2024.2365283. Epub 2024 Jun 23.
Horses are exquisitely sensitive to tetanus neurotoxin and are exposed to the risk of infection with throughout life. The vaccine against tetanus is highly effective at preventing disease, whereas tetanus in unvaccinated populations is associated with high mortality rates. Current guidelines in New Zealand and Australia for the available vaccine contain contradictions and limitations surrounding the optimal tetanus immunisation protocols for both adult horses and foals. This review critically evaluates the scientific literature on tetanus prophylaxis in horses within the context of equine practice and available products in New Zealand and Australia. The review was conducted by a panel of industry and specialist veterinarians to obtain agreement on nine equine tetanus prophylaxis guidelines for practising veterinarians. The primary protocol for tetanus toxoid (TT) immunisation consists of a three-dose series IM for all horses ≥ 6 months of age, and a four-dose series IM is proposed if commencing vaccination in foals between 3 and 6 months of age. Tetanus prophylaxis in foals < 3 months of age relies on passive immunity strategies. Following the completion of the primary protocol, a TT booster dose IM should be administered within 5 years, and every 5 years thereafter. When followed, these protocols should provide adequate protection against tetanus in horses. Additional tetanus prophylaxis guidelines are provided for veterinarians attending a horse experiencing a known "risk event" (e.g. wound, hoof abscess, surgery, umbilical infection). When a correctly vaccinated horse experiences a risk event, pre-existing immunity provides protection against tetanus. When an unvaccinated horse or one with unknown vaccination status, or a foal born to an unvaccinated dam, experiences a risk event, TT IM and tetanus antitoxin (TAT) 1,500 IU SC should be administered simultaneously at separate sites, and the TT primary immunisation protocol should subsequently be completed for the horse's respective age. In previously immunised pregnant broodmares, a TT booster dose administered 4-8 weeks prior to parturition optimises the transfer of passive immunity against tetanus to the newborn foal via colostrum; provided that post-natal IgG concentration in serum is > 800 mg/dL (8 g/L), such foals should be passively protected against tetanus up to 6 months of age. Survivors of clinical tetanus must still receive the primary protocol for vaccination against tetanus. In summary, all horses in New Zealand and Australia should be vaccinated against tetanus with protection maintained throughout life via TT booster doses, facilitated by accurate medical record keeping and client education.
马对破伤风神经毒素非常敏感,并且一生都面临感染破伤风的风险。破伤风疫苗在预防疾病方面非常有效,而未接种疫苗的人群中破伤风的死亡率很高。新西兰和澳大利亚目前针对可用疫苗的指南在成年马和马驹的最佳破伤风免疫方案方面存在矛盾和限制。本综述批判性地评估了新西兰和澳大利亚马破伤风预防的科学文献,以及该地区现有的产品。该综述由一组行业和专科兽医进行,以就九条针对执业兽医的马破伤风预防指南达成一致意见。破伤风类毒素(TT)免疫的主要方案是对所有≥ 6 月龄的马进行三剂肌内(IM)系列免疫,如果在 3 至 6 月龄的驹中开始接种,则建议进行四剂 IM 系列免疫。3 个月以下驹的破伤风预防依赖于被动免疫策略。完成主要方案后,应在 5 年内进行 TT 加强剂 IM 接种,此后每 5 年接种一次。如果遵循这些方案,应该可以为马提供足够的破伤风保护。还为遇到已知“风险事件”(例如伤口、蹄脓肿、手术、脐部感染)的兽医提供了额外的破伤风预防指南。当一匹经过正确接种的马遇到风险事件时,预先存在的免疫会提供针对破伤风的保护。当一匹未接种疫苗的马或其疫苗接种状况未知的马,或一匹出生于未接种疫苗的母马的驹遇到风险事件时,应同时在不同部位肌内(IM)注射 TT 和破伤风抗毒素(TAT)1500IU,然后应按照马的相应年龄完成 TT 初次免疫方案。对于先前免疫的妊娠母马,在分娩前 4-8 周接种 TT 加强剂,通过初乳将针对破伤风的被动免疫力最佳传递给新生驹;只要血清中的 IgG 浓度(8g/L)>800mg/dL,这样的驹就可以被动保护其免受破伤风的侵害,直到 6 月龄。破伤风临床存活者仍需接种破伤风初次免疫方案。总之,新西兰和澳大利亚的所有马都应接种破伤风疫苗,通过 TT 加强剂来维持终生保护,这得益于准确的病历记录和客户教育。